AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 34697111
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy of peg-IFN alpha 180 µg per week for 48 weeks combined with oral TDF 300 mg daily
Trial: 34697111
Drug: TDF monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TDF monotherapy 300 mg oral daily
Trial: 34697123
Drug: COMPASS (digital
FDA approved: no
EMA approved: no
PMDA approved: no
Description: COMPASS (digital cognitive-behavioural therapy programme) with six therapist contacts over 10 weeks
Trial: 34699302
Drug: Electronic medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electronic medication monitors (EMMs)
Trial: 34699945
Drug: Traditional Chinese
RxNorm normalized name: BORNEOL 1 g in 6.5 g / MINT 1 g in 6.5 g / ANGELICA DAHURICA ROOT 0.5 g in 6.5 g TOPICAL POWDER [Traditional Chinese Medicine Health Card and TCM Epidemic Prevention Card]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional Chinese Medicine (TCM) interventions
Trial: 34700344
Drug: VEN 200
RxNorm normalized name: Inoven 200 MG Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VEN 200 mg and IBR 420 mg
Trial: 34700344
Drug: All arms
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All arms (including various dosing combinations)
Trial: 34700344
Drug: Higher dosing
RxNorm normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher dosing combinations (IBR 560 mg and VEN 400 mg)
Trial: 34702064
Drug: Intensive treatment
RxNorm normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive treatment (target SBP, 130-140 mm Hg)
Trial: 34702064
Drug: Guideline-recommended treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guideline-recommended treatment (target SBP <180 mm Hg)
Trial: 34702124
Drug: VARIVAX™ 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VARIVAX™ 0.5 mL (1 dose for ages 12 months-12 years; 2 doses 6 weeks apart for ages 13-17 years)
Trial: 34702336
Drug: TAPER (Team
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAPER (Team Approach to Polypharmacy Evaluation and Reduction)
Trial: 34702811
Drug: sintilimab 200
RxNorm normalized name: Sintilimab
DrugBank: Sintilimab (DB15765)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sintilimab 200 mg intravenously every 3 weeks for up to 24 months
Trial: 34706885
Drug: HIC-H patients
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HIC-H patients treated with ICI monotherapy
Trial: 34706885
Drug: HIC-C patients
RxNorm normalized name: C.I. direct red 28 parent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HIC-C patients treated with ICI monotherapy
Trial: 34706885
Drug: HIC-H patients
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HIC-H patients treated with ICI plus chemotherapy
Trial: 34706885
Drug: HIC-C patients
RxNorm normalized name: C.I. direct red 28 parent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HIC-C patients treated with ICI plus chemotherapy
Trial: 34711577
Drug: QuantiFERON test
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: QuantiFERON test positive patients receiving antituberculosis treatment (ATT) for 6 months
Trial: 34711577
Drug: QuantiFERON test
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: QuantiFERON test value >2 IU/mL
Trial: 34711577
Drug: QuantiFERON test
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: QuantiFERON test threshold of 4 IU/mL
Trial: 34711663
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of peptide vaccination with immune checkpoint inhibition
Trial: 34711938
Drug: Inhaled nitric
RxNorm normalized name: nitric oxide Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled nitric oxide (iNO) for 24-96 hours during the first 0-7 days after birth
Trial: 34712113
Drug: Mesenchymal stromal
RxNorm normalized name: Mesenchymal Stromal Cells
DrugBank: Human Umbilical Cord Mesenchymal Stem Cells (DB15726)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mesenchymal stromal cells (MSCs) administered through the internal carotid arteries
Trial: 34712117
Drug: Retinal oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Retinal oxygen metabolism assessment in RMS patients
Trial: 34712229
Drug: Low Dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low Dose Radiation Therapy (LDRT) with a single dose per fraction of 0.5Gy
Trial: 34712229
Drug: Low Dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low Dose Radiation Therapy (LDRT)
Trial: 34712513
Drug: Neoadjuvant treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant treatment with intravenous PD-1 inhibitor toripalimab (240 mg), carboplatin (AUC 5), and pemetrexed (500 mg/m2) for three cycles.
Trial: 34712928
Drug: Direct-acting antivirals
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Direct-acting antivirals (DAAs) - sofosbuvir with an NS5A inhibitor (ledipasvir, daclatasvir or velpatasvir)±ribavirin
Trial: 34712959
Drug: Endocrine therapy
RxNorm normalized name: ENDOCRINE THERAPY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endocrine therapy (letrozole) combined with CDK inhibitor ribociclib
Trial: 34712959
Drug: Endocrine therapy
RxNorm normalized name: ENDOCRINE THERAPY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endocrine therapy (letrozole) alone
Trial: 34713017
Drug: Internet Cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internet Cognitive Behavioral Therapy with additional face-to-face outpatient psychotherapy (ICBT+)
Trial: 34713017
Drug: Internet Cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internet Cognitive Behavioral Therapy without additional face-to-face outpatient psychotherapy (ICBT)
Trial: 34713782
Drug: Statin treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Statin treatment in patients with ischemic heart disease (IHD)
Trial: 34713782
Drug: Angiotensin-converting enzyme
RxNorm normalized name: ACE - Angiotensin-converting enzyme
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Angiotensin-converting enzyme inhibitors (ACEI)/angiotensin receptor antagonists in patients with IHD, arterial hypertension, chronic heart failure (CHF), and atrial fibrillation
Trial: 34713782
Drug: Beta-blockers in
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-blockers in patients with IHD, arterial hypertension, chronic heart failure (CHF), and atrial fibrillation
Trial: 34713782
Drug: Oral anticoagulants
RxNorm normalized name: CPDA-1 Anticoagulant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral anticoagulants (OAC), primarily direct OAC, clopidogrel/prasugrel/ticagrelor in patients with IHD
Trial: 34713782
Drug: Oral antihyperglycemic
RxNorm normalized name: ANTIHYPOGLYCEMICS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral antihyperglycemic therapy in patients with type 2 diabetes mellitus (DM)
Trial: 34713782
Drug: Spironolactone treatment
RxNorm normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Spironolactone treatment in patients with CHF
Trial: 34713782
Drug: Inhaled corticosteroids
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled corticosteroids (iCS) in patients with chronic obstructive pulmonary disease (COPD)
Trial: 34714555
Drug: Pomalidomide plus
RxNorm normalized name: Pomalidomide
DrugBank: Pomalidomide (DB08910)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Pomalidomide plus low-dose dexamethasone (POM/DEX)
Trial: 34714708
Drug: Craniospinal RT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Craniospinal RT dose of 23.4 Gy for average-risk patients and 36-39.6 Gy for high-risk patients, boost dose of 55.8 Gy to the tumor bed.
Trial: 34714708
Drug: Increasing RT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Increasing RT dose to the corpus callosum (CC) or frontal white matter (WM) and hippocampus.
Trial: 34716177
Drug: Adavosertib 300
RxNorm normalized name: Adavosertib
DrugBank: Adavosertib (DB11740)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adavosertib 300 mg daily on days 1 through 5 and 8 through 12 of a 21-day cycle
Trial: 34716198
Drug: Ipilimumab (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ipilimumab (1 mg/kg i.v. every 6 weeks) plus Nivolumab (240 mg i.v. every 2 weeks)
Trial: 34716965
Drug: Ultrasound-guided conventional
RxNorm normalized name: ULTRASOUND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasound-guided conventional radiofrequency (RF) treatment of the genicular nerves
Trial: 34717057
Drug: Serum anti-Müllerian
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serum anti-Müllerian hormone (AMH) levels measured using the Elecsys AMH Plus immunoassay
Trial: 34717608
Drug: Non-ablative radiofrequency
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-ablative radiofrequency (RF) treatment (41°C) for five sessions with one week intervals
Trial: 34717717
Drug: Adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant chemotherapy plus chemoradiotherapy (experimental group)
Trial: 34717717
Drug: Adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant chemotherapy alone (control group)
Trial: 34718447
Drug: Oral treprostinil
RxNorm normalized name: Treprostinil
DrugBank: Treprostinil (DB00374)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Oral treprostinil for 1 year
Trial: 34718493
Drug: Warfarin (INR:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warfarin (INR: 2-2.5) and Aspirin (withheld after first bleeding episode)
Trial: 34718493
Drug: Post-implant vWf:Ag
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Post-implant vWf:Ag and vWf:CB
Trial: 34718501
Drug: Surgical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical treatment for post-infarction PMR with mitral valve replacement and concomitant coronary artery bypass grafting (CABG) in 57% of cases.
Trial: 34718501
Drug: Surgical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical treatment for post-infarction PMR.
Trial: 34718501
Drug: Surgical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical treatment for post-infarction PMR with concomitant CABG.
Trial: 34718636
Drug: Higher antibodies
RxNorm normalized name: digoxin antibodies Fab fragments Injection [DigiFab]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher antibodies to Ae. aegypti salivary proteins
Trial: 34718859
Drug: High-LA diet
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-LA diet (30, 40, or 50 ml of sunflower oil daily for 4 weeks)
Trial: 34718859
Drug: High-LA diet
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-LA diet (30, 40, or 50 ml of sunflower oil daily for 4 weeks) in FADS1 rs174550-CC genotype
Trial: 34718884
Drug: NOAC (non-vitamin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NOAC (non-vitamin K-dependent oral antagonists)
Trial: 34718884
Drug: In-hospital treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In-hospital treatment after stroke
Trial: 34719198
Drug: Repeated intrathecal
RxNorm normalized name: eicosyl povidone (2 eicosyl branches-repeat)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repeated intrathecal injections of autologous mesenchymal stem cells, dosage and duration not available
Trial: 34722242
Drug: AGIG chemo-immunotherapy
RxNorm normalized name: Chem-Star Recover
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AGIG chemo-immunotherapy regimen (nab-paclitaxel + gemcitabine + IL-2 + GM-CSF)
Trial: 34722269
Drug: Regionally administered
RxNorm normalized name: no vaccine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regionally administered melphalan
Trial: 34722563
Drug: MMGA (multimodal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MMGA (multimodal general anesthesia) using intravenous remifentanil, ketamine, dexmedetomidine, magnesium, and bupivacaine as a pecto-intercostal fascial block.
Trial: 34722661
Drug: Anti-inflammatory medications,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-inflammatory medications, specific type and dosage not available
Trial: 34722810
Drug: Moderately hypofractionated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderately hypofractionated intensity-modulated proton therapy (IMPT) targeting the prostate/seminal vesicles and pelvic lymph nodes, 6750 cGyRBE for prostate and 4500 cGyRBE for pelvic lymph nodes in 25 daily fractions, all received androgen-deprivation therapy.
Trial: 34724115
Drug: 4SCAR-GD2 T-cell
RxNorm normalized name: CD4CAR T cells
DrugBank: Anti-CD4 CAR T-cell therapy (DB17281)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4SCAR-GD2 T-cell treatment
Trial: 34724226
Drug: Molibresib 75
RxNorm normalized name: Molibresib
DrugBank: Molibresib (DB16239)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Molibresib 75 mg once daily
Trial: 37587492
Drug: Intravenous arginine
RxNorm normalized name: Arginine
DrugBank: Arginine (DB00125)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous arginine therapy
Trial: 34724453
Drug: Daily step
RxNorm normalized name: PostDay One-Step
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Daily step counts measured using armband accelerometers worn for 7 days, with a median of 1170 steps daily.
Trial: 34724453
Drug: Daily step
RxNorm normalized name: PostDay One-Step
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Daily step counts measured using armband accelerometers worn for 7 days.
Trial: 34725072
Drug: IV DEXA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV DEXA (24 mg)
Trial: 34725077
Drug: In-bed leg
RxNorm normalized name: Crab leg
DrugBank: Crab leg (DB11011)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In-bed leg cycling for 30 minutes daily for 14 consecutive days, initiated within 48 hours of spinal surgery.
Trial: 34725108
Drug: mTOR inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mTOR inhibitors (mTORis)
Trial: 34725289
Drug: Tregocel® nutraceutical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tregocel® nutraceutical supplement
Trial: 34726610
Drug: Peer-delivered eHealth
RxNorm normalized name: smallpox vaccine live, New York City Board of Health vaccinia strain Injectable Solution [ACAM2000]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peer-delivered eHealth intervention (3 sessions delivered weekly over 3 weeks)
Trial: 34726887
Drug: SY-5609, a
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SY-5609, a selective, noncovalent inhibitor of CDK7
Trial: 34727366
Drug: HS-10234 25
RxNorm normalized name: sodium fluoride 0.00234 MG/MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HS-10234 25 mg daily for 7 days (D1-D7) followed by emtricitabine 200 mg QD for 7 days (D8-D14)
Trial: 34727366
Drug: Emtricitabine 200
RxNorm normalized name: emtricitabine 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Emtricitabine 200 mg QD for 7 days (D1-D7) followed by HS-10234 25 mg QD for 7 days (D8-D14)
Trial: 34727875
Drug: nab-paclitaxel (Abraxane,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nab-paclitaxel (Abraxane, 125 mg/m2, D1, D8, D15 every 28 days)
Trial: 34727956
Drug: MedReviewRx software
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MedReviewRx software used for medication reviews
Trial: 34728052
Drug: Mandibular advancement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mandibular advancement device therapy
Trial: 34728440
Drug: Monthly videoconference-psychotherapy
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Monthly videoconference-psychotherapy
Trial: 34728440
Drug: Weekly videoconference-psychotherapy
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Weekly videoconference-psychotherapy plus message-based care
Trial: 34729148
Drug: Non-Optimal Medical
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-Optimal Medical Therapy (non-OMT)
Trial: 34729767
Drug: Hyperfibrinolysis defined
RxNorm normalized name: refined almond oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperfibrinolysis defined as enzymatic fibrinolysis index (ROTEM EXTEM ML minus ROTEM APTEM ML) above 15%
Trial: 34730535
Drug: Smartphone-enhanced behavioral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Smartphone-enhanced behavioral activation treatment (Life Enhancement Treatment for Substance Use)
Trial: 34730541
Drug: Online therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Online therapy
Trial: 34730541
Drug: Face-to-Face therapy
RxNorm normalized name: FACE SHIELD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Face-to-Face therapy (F2F)
Trial: 34732500
Drug: Lengthened dosing
RxNorm normalized name: PROPYLENE GLYCOL 0.1 g in 1 g TOPICAL CREAM [Eyelash and Eyebrow Lengthener]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lengthened dosing interval (from 8 to 12 weeks for infliximab users and from 2 to 3 weeks for adalimumab users)
Trial: 34732500
Drug: Lengthened dosing
RxNorm normalized name: PROPYLENE GLYCOL 0.1 g in 1 g TOPICAL CREAM [Eyelash and Eyebrow Lengthener]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lengthened dosing interval
Trial: 34732682
Drug: Atazanavir 300
RxNorm normalized name: atazanavir 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atazanavir 300 mg and Cobicistat 150 mg orally once daily during the second trimester
Trial: 34732682
Drug: Atazanavir 300
RxNorm normalized name: atazanavir 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atazanavir 300 mg and Cobicistat 150 mg orally once daily during the third trimester
Trial: 34732682
Drug: Atazanavir 300
RxNorm normalized name: atazanavir 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atazanavir 300 mg and Cobicistat 150 mg orally once daily postpartum
Trial: 34734199
Drug: Treatment-as-usual services
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment-as-usual services
Trial: 34734223
Drug: Light drinkers
RxNorm normalized name: kaolin light
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Light drinkers (>2 to 10 g/d)
Trial: 34734223
Drug: Moderate drinkers
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderate drinkers (>10 to 30 g/d)
Trial: 34734223
Drug: Heavy drinkers
RxNorm normalized name: heavy mineral oil
DrugBank: Mineral oil (DB11057)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heavy drinkers (>30 g/d)
Trial: 34734223
Drug: Nondrinkers (0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nondrinkers (0 g/d) and very light drinkers (>0 to 2 g/d)
Trial: 34734507
Drug: Drug-induced IL-22
RxNorm normalized name: Ile
DrugBank: Isoleucine (DB00167)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Drug-induced IL-22 releasing cells
Trial: 34734507
Drug: Drug-induced IFN-γ
RxNorm normalized name: IFNγ
DrugBank: Interferon Gamma (DB15753)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug-induced IFN-γ releasing cells
Trial: 34734507
Drug: Drug-induced GrB
RxNorm normalized name: GRb 1
DrugBank: Ginsenoside Rb1 (DB06749)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug-induced GrB releasing cells
Trial: 34734835
Drug: 12 sessions
RxNorm normalized name: Alpinia Sessilis Root
DrugBank: Kaempferia galanga root (DB14288)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12 sessions of twice weekly EMDR plus treatment as usual
Trial: 34735860
Drug: Acalabrutinib 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acalabrutinib 200 mg twice daily as monotherapy
Trial: 34736130
Drug: Extended-release buprenorphine
RxNorm normalized name: Buprenorphine Extended-Release Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended-release buprenorphine injections (BUP-XR), administered monthly after a minimum of 7 days on 8-32 mg of sublingual buprenorphine (±naloxone)
Trial: 34736497
Drug: Scalp nerve
RxNorm normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Scalp nerve blocks with 0.5% bupivacaine plus dexamethasone (exact dosage not specified)
Trial: 34736503
Drug: Conductive hearing
RxNorm normalized name: carbamide peroxide
DrugBank: Carbamide peroxide (DB11129)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conductive hearing loss or combination of conductive and sensorineural hearing loss
Trial: 34736538
Drug: Idiographic network
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Idiographic network analysis for personalized treatment targets
Trial: 34736538
Drug: Selection methods
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selection methods for treatment targets
Trial: 34736789
Drug: Preoperative soluble
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preoperative soluble urokinase plasminogen activator receptor
Trial: 34736789
Drug: Preoperative soluble
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preoperative soluble urokinase plasminogen activator receptor between 5.5 and 10 ng/mL
Trial: 34736789
Drug: Preoperative soluble
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preoperative soluble urokinase plasminogen activator receptor >10 ng/mL